United States: Health Care Policy Newsletter - 11 June 2018

Foley's Bipartisan Public Policy Team  is pleased to share our "Public Policy Health Care Newsletter" in which we compile the latest health care policy news and legislation.

*Please note that we publish this newsletter only when Congress is in session.


Legislation and Committee Activity

House Passes First Package of Appropriations Bills – The House approved a package today – commonly called a "mini-bus" – of three fiscal year 2019 Appropriations bills, including Energy and Water, Military Construction and Veterans Affairs, and the Legislative Branch. Read More

Roll Call: Congress' Focus on Opioids Misses Larger Crisis Congress faced a startling public health and political problem throughout 2016 as the number of people dying from opioid addiction climbed. The number of Americans succumbing to drug overdoses more than tripled between 1999 and 2015, affecting a whiter and more geographically diverse population than previous drug crises. Lawmakers ultimately approved some modest policies aimed at curbing prescription drug abuse and provided $1 billion to support state efforts. Read More

Politico: Bill Cassidy Doesn't Want to be 'Don Quixote' on ACA Repeal – Sen. Bill Cassidy (R-LA), co-author of a high-profile Obamacare repeal bill, isn't so sure Congress should take another crack at undoing the law this year. However, he said lawmakers should move on legislation to make health care more affordable. Read More Read More

Hearing on Lowering Costs and Expanding Access to Health care through Consumer – Directed Health Plans On Wednesday, the House Ways and Means Committee held a hearing on lowering costs and expanding access to health care through consumer-directed health plans. Read More Read More

Walden and Burgess on 2018 Medicare Trustees Report Energy and Commerce Committee Chairman Greg Walden (R-OR) and Health Subcommittee Chairman Michael C. Burgess, M.D. (R-TX) issued the following statement after the release of the 2018 Medicare Trustees Report. Read More Read More

Bipartisan E&C, Senate HELP Leaders Press HHS for Answers on Health Care Cybersecurity Efforts – On Tuesday, bipartisan and bicameral health care leaders sent a letter to HHS raising concerns about the department's implementation of a portion of the Cybersecurity Information Sharing Act (CISA) of 2015. The leaders requested information regarding the "Cyber Threat Preparedness Report" (CTPR), as well as other important status updates. Read More

HHS Secretary Azar Testifies Before Education and Workforce Committee On Wednesday, the Committee on Education and the Workforce, chaired by Rep. Virginia Foxx (R-NC), held an oversight hearing with Department of Health and Human Services (HHS) Secretary Alex Azar to review the Department's policies and priorities. Read More

Alexander, Bennet Introduce "PREEMIE" Bill to Give Infants Hope for Healthier Lives On Thursday, Sens. Lamar Alexander (R-TN) and Michael Bennet (D-CO) introduced the PREEMIE Act (S. 3029) to revise and extend the Prematurity Research Expansion and Education for Mothers who deliver Infants Early Act. Reps. Anna Eshoo (D-CA) and Leonard Lance (R-NJ) are expected to introduce companion legislation in the House of Representatives. Read More

Politico: McConnell Cancels Most of August Recess Sen. Majority Leader Mitch McConnell (R-KY) is canceling all but a week of the Senate's traditional August recess, hoping to keep vulnerable Democrats off the campaign trail and confirm as many of President Donald Trump's judicial and executive branch nominees as possible. Read More


Statement from the Press Secretary Regarding the Youth Opioid Prevention Ad Campaign Today, the Administration unveiled the first set of public awareness ads to combat the opioid crisis. The first set of ads is focused on preventing young adults, ages 18-24, from misusing or abusing opioids. Read More

Chairman Pai Proposes Funding Increase for Rural Health Care Program – Federal Communications Commission Chairman Ajit Pai announced that he has circulated a draft order to his colleagues that would take immediate action to significantly increase funding for the Universal Service Fund's Rural

Health Care Program. Read More


Politico: Trump Seeks to Reorganize the Federal Government – The Trump administration is preparing to release a sweeping plan for reorganizing the federal government that includes a major consolidation of welfare programs — and a renaming of the Health and Human Services Department. Read More

Readout of HHS Secretary Azar's Roundtable with Medical Device Leaders On Thursday, HHS Secretary Alex Azar held a roundtable discussion with leaders from medical device companies and the industry group AdvaMed. The gathering was part of ongoing efforts at HHS to explore ways to break down barriers to innovation as part of the Trump Administration's work to improve health care in the United States. Read More

Health Care Informatics: The Push Towards Value – Based Care is Forcing the HIT Vendor Market Forward The health care policy and payment landscape is rapidly evolving, with the move to value-based care models a driving force behind current health care reform efforts. Case in point: in a recent speech at the World Health Care Congress, Health and Human Services (HHS) Secretary Alex Azar laid out his agency's overall policy strategy and cited accelerating the value-based transformation of the Health care system as a top priority. Read More

NIH releases strategic plan for data science Storing, managing, standardizing and publishing the vast amounts of data produced by biomedical research is a critical mission for the National Institutes of Health. In support of this effort, NIH today released its first Strategic Plan for Data Science that provides a roadmap for modernizing the NIH-funded biomedical data science ecosystem. Read More


The Hill: Watchdog Report Finds surge in Medicare Drug Spending – Medicare spending on prescription drugs has surged in recent years, despite a drop in the number of prescriptions, according to a new report. The report from the Department of Health and Human Services (HHS) inspector general finds that Medicare Part D spending for brand-name drugs rose by 62 percent from 2011 to 2015, from $49 billion to $80 billion. Read More

Medicare Funds Drying Up Faster Than Estimated – The Medicare trust fund will be insolvent by 2026, three years earlier than estimates released by the Trump administration last year. That's partly due to the Tax Cuts and Jobs Act which called for eliminating the individual mandate, according to the 2018 Medicare Trustee Report released Tuesday. Read More

Fierce Health Care: CMS Unveils Medicaid/CHIP 'Scorecard' Data – The Trump administration released the inaugural Medicaid and CHIP "scorecard" on June 4, which is intended to reveal how states are performing under the programs. Read More

Modern Health Care: White House Officials Call for ACO Rule Changes – Accountable Care Organizations are failing to meet their promise to save Medicare money, and regulations governing the model need to change, according to senior White House official. Read More

GAO Report: Medicare Needs Better Information to Reduce the Risk of Harm to Beneficiaries – In late May, GAO released a report of Medicare's efforts to reduce inappropriate opioid prescribing. We suggested ways to help Medicare collect information on doctor investigations and at-risk beneficiaries that could help it determine whether its efforts are working. Read More

GAO Report: CMS Should Take Steps to Mitigate Program Risks in Managed Care – On Wednesday, CMS released a report on Steps to Mitigate Program Risks in Managed Care. Read More


FDA Takes Action Against 53 Websites Marketing Unapproved Opioids as Part of a Comprehensive Effort to Target Illegal Online Sales – The U.S. Food and Drug Administration announced that it has warned nine online networks, operating a total of 53 websites, that they must stop illegally marketing potentially dangerous, unapproved and misbranded versions of opioid medications, including tramadol and oxycodone. Read More

FDA Approves First Biosimilar to Neulasta to Help Reduce the Risk of Infection During Cancer Treatment – On Monday, the FDA approved Fulphila as the first biosimilar to Neulasta to decrease the chance of infection as suggested by febrile neutropenia (fever, often with other signs of infection, associated with an abnormally low number of infection-fighting white blood cells), in patients with non-myeloid (non-bone marrow) cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia. Read More

Veterans Affairs

USA Today: Trump Signs VA Law to Provide Veterans More Private Health Care Choices – President Trump signed legislation Wednesday paving the way for a major overhaul of the Department of Veterans Affairs and expanded access for veterans to VA-funded care in the private sector. Read More


Gov. Northam Signs Virginia Budget, Medicaid Expansion Bill – Governor Ralph Northam signed two bills Thursday that will fund the Commonwealth of Virginia's government for the rest of Fiscal Year 2018 and all of Fiscal Years 2019 and 2020. Read More

ABC News: Medicaid Work Requirement Bill Sent to Michigan Governor – The Republican-led Michigan Legislature on Thursday gave final approval to a bill requiring able-bodied adults in the state's Medicaid expansion program to meet work or job-related requirements, sending it to Gov. Rick Snyder for his expected signature. Read More

Washington Post: Trump Administration Won't Defend ACA in Case Brought by GOP States – The Trump administration said Thursday night that it will not defend the Affordable Care Act against the latest legal challenge to its constitutionality — a dramatic break from the executive branch's tradition of arguing to uphold existing statutes and a land mine for health insurance changes the ACA brought about. Read More


California – Sen. Dianne Feinstein (D-CA) and Lt. Gov Gavin Newsom won early victories. Feinstein will face Democratic State Senator Kevin De Leon and Newsom will face Republican John Cox.

Montana – State auditor and insurance commissioner Matt Rosendale will take on Senator Jon Tester (D-MT) in November.

New Mexico – Rep. Michelle Lujan Grisham (D-MN) clinched the Democratic nomination for governor.

Iowa – Democrat Pete D'Alessandro will face Rep. David Young (R-IA) in the Iowa 3rd district.

Vox: 5 Winners and 2 Losers From the First Set of this Week's Primary Elections – June 5 was the biggest primary day of the year — but it may take some time before all the election results are clear. Read More

On June 12, Maine, Nevada, North Dakota, South Carolina and Virginia will head to the polls.

The VA Mission Act of 2018 and Potential Opportunities for Providers – After a concerted effort, the bipartisan bill to reform the way care is delivered to Veterans has been signed into law. While there are a number of significant reforms, perhaps none are so critical as those related to the ability of Covered Veterans to receive their care outside of the current VA system. Read More

Orthopedics: The New Darling of Private Equity – The past decade has seen a tremendous amount of private equity investment in physician practice recapitalizations, primarily in hospital-based practices such as anesthesiology and radiology as well as "retail medicine practices" like dermatology and ophthalmology/optometry, to name a few. Read More

Looking Ahead

The House and Senate are Both in Session Next Week.

Majority Leader Kevin McCarthy (R-CA) announced in an end-of-week leadership colloquy that the House will vote on several opioid measures next week. The House will consider H.R. 2851 that would establish a new category of synthetic opioids and other drugs under the Controlled Substances Act; H.R. 5735 that would set aside low-income housing vouchers to help people recovering from addiction; and H.R. 5788 that would close loopholes in international shipping to stop the flow of synthetic opioids. First votes are Tuesday at 6:30pm; last votes are no later than 3:00pm.

On Monday, the House Rules Committee will begin setting debate parameters for a synthetic analogue control measure – Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 (H.R. 2851). Read More

On Tuesday, the Senate Judiciary Committee will hold a markup on the combined opioid response package – the Preventing Drug Diversion Act of 2018 (S. 2837). Read More

On Tuesday, the Senate HELP Committee will hold a hearing on Trump's drug pricing plan. HHS Secretary Alex Azar will testify. Read More

On Tuesday, the Senate Finance Committee will hold a markup on the Helping to End Addiction and Lessen (HEAL) Substance Use Disorders Act of 2018, which seeks to improve Medicare, Medicaid and human services programs' response to the opioid crisis. Read More

On Wednesday, the House Veteran Affairs Committee will hold a hearing on six Health care measures and two draft bills. Read More

On June 19, the Senate HELP Committee will hold a hearing on the Effective Administration of the 340B Drug Pricing Program. Read More

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions